Aclarion Inc
aclarion.comWhat Do They Do?
Sells Nociscan software that analyzes MRI spectroscopy data to help physicians identify painful lumbar discs and guide treatment for patients with chronic low back pain.
10-K for FY2025, filed Mar 18, 2026Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), and proprietary biomarkers to optimize…View ↗
Aclarion has developed a software application called NOCISCAN® which uses the existing MRS capabilities of many commercially available…View ↗
The first application of Aclarion’s technology is focused on improving surgical decision making when surgical intervention is being…View ↗
How Do They Make Money?
Customers pay a negotiated amount for each Nociscan report. The company invoices according to the sales arrangement, and payment is generally due 30 to 90 days after the invoice.
10-K for FY2025, filed Mar 18, 2026Step 1 – Identify The Contract With A Customer – A contract exists when there is legally enforceable agreement between the Company and the…View ↗
Step 2 – Identify The Performance Obligations In The Contract – The Company contracts with customers contain a single performance…View ↗
Step 3 – Determine The Transaction Price – The transaction price is the negotiated consideration specified in the contract for the Nociscan…View ↗
Step 5 – Recognize Revenue When (Or As) The Entity Satisfies A Performance Obligations – Revenue is recognized at a point in time when…View ↗
$75.7K
-
10-K for FY2025, filed Mar 18, 2026
$75.7K ↗
Who Are Their Customers?
Physicians order Nociscan reports for patients. Imaging centers with compatible MRI scanners provide the spectroscopy data used to prepare the reports; the company reports sales into the UK market.
10-K for FY2025, filed Mar 18, 2026Aclarion has developed a software application called NOCISCAN® which uses the existing MRS capabilities of many commercially available…View ↗
Because we believe that spectroscopy is not widely used for any clinical purposes today, there are practical limitations to the market…View ↗
Total revenues for the year ended December 31, 2025, were $75,730, which was an increase of $30,006 or 65.6%, from $45,724 for the year…View ↗
Do Revenues Turn Into Profits?
No. It lost $7.2M in FY2025.
10-K for FY2025, filed Mar 18, 2026
−$7.1MView ↗
10-K for FY2025, filed Mar 18, 2026
−$7.2MView ↗
10-K for FY2025, filed Mar 18, 2026
−$7.2MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$2.7MView ↗
- ▲ +72% (Loss)
- vs −$1.6M in Q2 FY2025
-
Apr 22, 2026
Aclarion authorized a share repurchase program of up to $2.5 million
The program may use existing cash and does not require the company to repurchase any shares.
Sources
8-K, filed Apr 22, 2026
On April 21, 2026, the board of directors of Aclarion, Inc. (the “Company”) authorized and approved a share repurchase program. Under the…View ↗
Who Do They Compete With?
Competes with SIEMENS
10-K for FY2025, filed Mar 18, 2026Because we believe that spectroscopy is not widely used for any clinical purposes today, there are practical limitations to the market…View ↗
Loading...
